London, 10 July 2023 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced the appointment of Simon Ramsden as Chief Financial Officer (CFO).
“Simon brings to Resolution a track record of finance management in life sciences, with experience at all stages of the product life-cycle from research to commercialisation,” said Edward Hodgkin, Managing Partner of Syncona Investment Management Limited and CEO of Resolution. “His background is key to our ambition to build a fully-integrated cell therapy business.”
“I’m delighted to be joining Resolution during this period of rapid growth as the Company advances its pipeline,” added Simon Ramsden. “Resolution is the leader in the development of macrophage cell therapy for advanced liver disease and I look forward to working with the experienced team to bring new treatments to patients with high unmet medical need.”
Simon Ramsden brings broad corporate and commercial finance experience in the pharmaceutical and biotechnology industry to Resolution. Since completing his training with Ernst and Young, he has spent 13 years in the life science sector across multiple financial disciplines including M&A, Corporate Finance, Financial Reporting, Commercial Finance and R&D Finance. Simon spent 9 years at GSK Plc in the UK and Belgium in roles of increasing responsibility in the corporate team and within operating units (Pharmaceuticals, Vaccines and Consumer Health) with his final role being Finance Director for the Consumer Health R&D unit. In 2020, Simon joined EUSA Pharma, a private equity backed rare disease company, where he held overall financial responsibility across all areas as Vice President & Head of Global Finance and supported the sale of the business to Recordati SpA in 2022. Most recently he was CFO for Closed Loop Medicine Ltd, a TechBio start-up based in Cambridge. He gained his BSc (Hons) degree in Medical Biochemistry from the University of Birmingham and is a member of the Institute of Chartered Accountants of Scotland.
– Ends –
|+44 (0)7818 430877
Notes for Editors:
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com